WAY-204688

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H31F3N2O2
Molecular Weight	556.6173
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=CC=C1[C@H](C2=CC=CC3=CC=CC=C23)[C@@](C)(C#N)C(=O)N4CCC(CC4)C5=CC=CC(=C5)C(F)(F)F

InChI

InChIKey=JZPONCMNBSEYQW-CQTOTRCISA-N

InChI=1S/C34H31F3N2O2/c1-33(22-38,32(40)39-19-17-23(18-20-39)25-11-7-12-26(21-25)34(35,36)37)31(29-14-5-6-16-30(29)41-2)28-15-8-10-24-9-3-4-13-27(24)28/h3-16,21,23,31H,17-20H2,1-2H3/t31-,33+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C34H31F3N2O2
Molecular Weight	556.6173
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800022078https://www.ncbi.nlm.nih.gov/pubmed/29067315 | https://www.ncbi.nlm.nih.gov/pubmed/24489014 | https://adisinsight.springer.com/drugs/800029247
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16317384 | https://www.ncbi.nlm.nih.gov/pubmed/17902637

Juvantia Pharma and Orion developed ORM-12741, also known as ORM-10921, a novel selective antagonist of alpha-2C adrenoceptors for the treatment of depression and Alzheimer's disease. ORM-12741 participated in phase II clinical trial where was evaluated the safety and efficacy of the drug in patients with Alzheimer's disease. In spite of the successfully completed phase II, further study of the drug for this disease was discontinued. In addition, ORM-12741 participated in clinical trial phase II to prove the concept that this drug could prevent blood vessel spasms for Raynaud's phenomenon. Raynaud's phenomenon is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. However, this study was terminated because of the recommendation by study Data and Safety Monitoring Committee to the sponsor following the interim analysis of 8 subjects.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 75 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637	Interacts 323
Nuclear factor NF-kappa-B complex 11 Target ID: CHEMBL2094258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Septic shock 21 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16317384	Primary		Preclinical	Unknown Approved Use Unknown
Rheumatoid arthritis 316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17902637 http://adisinsight.springer.com/drugs/800022078	Primary		Phase I 428	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.	2014 May	24489014
The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat.	2017 Feb	27749317
Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease.	2017 Jan	29067315

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:35:43 UTC 2023` Edited by `admin` on `Fri Dec 15 15:35:43 UTC 2023`
Record UNII	QT9VF4MW6U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

WAY-204688

Code

English

SIM688

Code

English

WAY204688

Code

English

(2R)-2-((S)-(2-METHOXYPHENYL)-(1-NAPHTHYL)METHYL)-2-METHYL-3-OXO-3-(4-(3-(TRIFLUOROMETHYL)PHENYL)-1-PIPERIDYL)PROPANENITRILE

Systematic Name

English

PIPERIDINE, 1-((2S,3S)-2-CYANO-3-(2-METHOXYPHENYL)-2-METHYL-3-(1-NAPHTHALENYL)-1-OXOPROPYL)-4-(3-(TRIFLUOROMETHYL)PHENYL)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

9829162